Navigating diagnostic and treatment decisions in non‐small cell lung cancer: expert commentary on the multidisciplinary team approach
Non‐small cell lung cancer (NSCLC) accounts for approximately one in five cancer‐related
deaths, and management requires increasingly complex decision making by health care …
deaths, and management requires increasingly complex decision making by health care …
Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review
EB Garon, C Visseren-Grul, MT Rizzo, T Puri… - Frontiers in …, 2023 - frontiersin.org
Introduction In the REVEL trial, ramucirumab plus docetaxel demonstrated significant
improvements in overall survival (OS), progression-free survival (PFS), and overall response …
improvements in overall survival (OS), progression-free survival (PFS), and overall response …
Real-world treatment and survival of patients with advanced non-small cell lung cancer: a German retrospective data analysis
F Hardtstock, D Myers, T Li, D Cizova, U Maywald… - BMC cancer, 2020 - Springer
Background The objective of this study was to describe the real-world treatment and overall
survival (OS) of German patients with a diagnosis of advanced non-small cell lung cancer …
survival (OS) of German patients with a diagnosis of advanced non-small cell lung cancer …
Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of …
RP Insinga, DJ Vanness, JL Feliciano… - … medical research and …, 2019 - Taylor & Francis
Objective: To describe the cost-effectiveness of pembrolizumab plus chemotherapy
(carboplatin and paclitaxel or nab-paclitaxel; P+ C) in metastatic, squamous, non-small-cell …
(carboplatin and paclitaxel or nab-paclitaxel; P+ C) in metastatic, squamous, non-small-cell …
Cost–effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA
M Huang, GL Lopes, RP Insinga, T Burke… - …, 2019 - Taylor & Francis
Aim: This analysis aimed to evaluate the cost–effectiveness of pembrolizumab monotherapy
as first-line treatment in advanced non-small-cell lung cancer patients with a programmed …
as first-line treatment in advanced non-small-cell lung cancer patients with a programmed …
CDK4/6 Inhibitor Efficacy in ESR1-Mutant Metastatic Breast Cancer
MR Lloyd, JO Brett, A Carmeli, CM Weipert… - NEJM …, 2024 - evidence.nejm.org
Background In estrogen receptor–positive metastatic breast cancer, ESR1 mutations (ESR1
m) are a common mechanism of acquired resistance to aromatase inhibitors (ArIh) …
m) are a common mechanism of acquired resistance to aromatase inhibitors (ArIh) …
[HTML][HTML] Atezolizumab compared to chemotherapy for first-line treatment in non-small cell lung cancer with high PD-L1 expression: a cost-effectiveness analysis from …
S Cheng, R Pei, J Li, B Li, L Tang, T Yin… - Annals of translational …, 2021 - ncbi.nlm.nih.gov
Background The IMpower110 trial revealed that atezolizumab treatment had significantly
longer overall survival (OS) than chemotherapy in non-small cell lung cancer (NSCLC) …
longer overall survival (OS) than chemotherapy in non-small cell lung cancer (NSCLC) …
Sequential therapy with ramucirumab and/or checkpoint inhibitors for non-small-cell lung cancer in routine practice
C Molife, LM Hess, ZL Cui, XI Li, J Beyrer… - Future …, 2019 - Taylor & Francis
Aim: To describe treatment patterns and outcomes for advanced/metastatic non-small-cell
lung cancer (aNSCLC) treated with single-agent or combination ramucirumab (ramucirumab …
lung cancer (aNSCLC) treated with single-agent or combination ramucirumab (ramucirumab …
Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non–Small-Cell Lung Cancer and …
PURPOSE This study assessed real-world survival among older patients with non–small-
cell lung cancer (NSCLC) and brain metastases (BMs) at diagnosis (synchronous BM [SBM]) …
cell lung cancer (NSCLC) and brain metastases (BMs) at diagnosis (synchronous BM [SBM]) …
[HTML][HTML] Temporal phenotyping by mining healthcare data to derive lines of therapy for cancer
W Meng, W Ou, S Chandwani, X Chen, W Black… - Journal of Biomedical …, 2019 - Elsevier
Lines of therapy (LOT) derived from real-world healthcare data not only depict real-world
cancer treatment sequences, but also help define patient phenotypes along the course of …
cancer treatment sequences, but also help define patient phenotypes along the course of …